PPARA and peripheral neuropathy: The resulting formulation (A190-ME) effectively reduced mechanical hypersensitivity in a chemotherapy induced peripheral neuropathy (CIPN) mouse model in a PPARα dependent fashion and was also found to be equally effective at reducing chronic inflammatory Complete Freund’s Adjuvant (CFA)-induced pain.